{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:22:11Z","timestamp":1781590931304,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T00:00:00Z","timestamp":1757116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["G00005068"],"award-info":[{"award-number":["G00005068"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118144","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:52:09Z","timestamp":1757170329000},"page":"118144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mitigating SARS-CoV-2\u2013exacerbated neuroinflammation and Alzheimer's pathology: Synthesis of quinoline-based dual inhibitors targeting cysteine and aspartyl proteases"],"prefix":"10.1016","volume":"300","author":[{"given":"Abid Hussain","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Balqees","family":"Gondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltaf","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-431X","authenticated-orcid":false,"given":"Abbas","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118144_bib1","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1021\/acs.jcim.0c00190","article-title":"Catalytic site pKa values of aspartic, cysteine, and serine proteases: constant pH MD simulations","volume":"60","author":"Hofer","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118144_bib2","doi-asserted-by":"crossref","first-page":"30433","DOI":"10.1074\/jbc.R800035200","article-title":"Proteases: multifunctional enzymes in life and disease","volume":"283","author":"L\u00f3pez-Ot\u00edn","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","article-title":"Proteases: history, discovery, and roles in health and disease","volume":"294","author":"Bond","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13195-020-00640-3","article-title":"Immediate and long-term consequences of COVID-19 infections for the development of neurological disease","volume":"12","author":"Heneka","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2025.118144_bib5","doi-asserted-by":"crossref","first-page":"121ps123","DOI":"10.1126\/scitranslmed.3003492","article-title":"Viral and inflammatory triggers of neurodegenerative diseases","volume":"4","author":"Deleidi","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118144_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"\u03b2-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118144_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118144_bib8","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1039\/D4RA08449G","article-title":"Dihydropyrimidine-2-thione derivatives as SARS-CoV-2 main protease inhibitors: synthesis, SAR and in vitro profiling","volume":"15","author":"Saeed","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118144_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117327","article-title":"Promising thiazolidinedione-thiazole based multi-target and neuroprotective hybrids for Alzheimer's disease: design, synthesis, in-vitro, in-vivo and in-silico studies","volume":"287","author":"Hussain","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.35772\/ghm.2024.01033","article-title":"BACE1 inhibitor drugs for the treatment of Alzheimer's disease: lessons learned, challenges to overcome, and future prospects","volume":"6","author":"Ghosh","year":"2024","journal-title":"Global Health & Medicine"},{"key":"10.1016\/j.ejmech.2025.118144_bib11","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1172\/JCI133737","article-title":"Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease","volume":"130","author":"Roy","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.118144_bib12","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib13","series-title":"Drug Design and Discovery in Alzheimer's disease","first-page":"40","article-title":"Chapter 2 - challenges in designing therapeutic agents for treating Alzheimer's disease-from serendipity to rationality","author":"Rashid","year":"2014"},{"key":"10.1016\/j.ejmech.2025.118144_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: successes, failures and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118144_bib15","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/ijms22063232","article-title":"Mechanisms of proteolytic enzymes and their inhibition in QM\/MM studies","volume":"22","author":"Els\u00e4sser","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118144_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118144_bib17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118144_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0006-291X(92)91136-E","article-title":"HIV-1 protease inhibitors containing statine : inhibitory potency and antiviral activity","volume":"188","author":"Fehrentz","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118144_bib19","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: a novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics","volume":"50","author":"Eketj\u00e4ll","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejmech.2025.118144_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ejmech.2025.118144_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40263-019-00613-7","article-title":"A close look at BACE1 inhibitors for alzheimer's disease treatment","volume":"33","author":"Das","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejmech.2025.118144_bib22","doi-asserted-by":"crossref","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","article-title":"P4-389: elenbecestat, E2609, a BACE inhibitor: results from a PHASE-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to ALZHEIMER'S disease","volume":"14","author":"Lynch","year":"2018","journal-title":"Alzheimer's Dement."},{"key":"10.1016\/j.ejmech.2025.118144_bib23","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","article-title":"The BACE\u20101 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118144_bib24","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118144_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (Nirmatrelvir\/Ritonavir): a new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118144_bib26","doi-asserted-by":"crossref","first-page":"16922","DOI":"10.1021\/acs.jmedchem.1c00409","article-title":"Perspectives on SARS-CoV-2 main protease inhibitors","volume":"64","author":"Gao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib27","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1021\/acs.jmedchem.6b00723","article-title":"Discovery of a Quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy","volume":"59","author":"Baraga\u00f1a","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133634","article-title":"A review: structure-activity relationship and antibacterial activities of quinoline based hybrids","volume":"1268","author":"Patel","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118144_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113220","article-title":"Synthetic and medicinal perspective of quinolines as antiviral agents","volume":"215","author":"Kaur","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.drudis.2012.11.003","article-title":"Quinolines: a new hope against inflammation","volume":"18","author":"Mukherjee","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118144_bib31","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/antiox12101853","article-title":"Quinoline derivatives: promising antioxidants with neuroprotective potential","volume":"12","author":"Hern\u00e1ndez-Ayala","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2025.118144_bib32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s11030-022-10581-8","article-title":"Quinolone: a versatile therapeutic compound class","volume":"27","author":"Dube","year":"2023","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2025.118144_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500279","article-title":"Recent advances of quinoline-based small molecules as kinase inhibitors (2020\u20132024)","volume":"20","author":"Sultan","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118144_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105240","article-title":"Divergent synthesis and elaboration of structure activity relationship for quinoline derivatives as highly selective NTPDase inhibitor","volume":"115","author":"Murtaza","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib35","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41467-025-56902-x","article-title":"Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates","volume":"16","author":"Jadhav","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118144_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118135","article-title":"Design, synthesis and activity evaluation of 4-(quinoline-2-yl)aniline derivatives as SARS-CoV-2 main protease inhibitors","volume":"121","author":"Bao","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib37","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1021\/jm200544q","article-title":"From fragment screening to in vivo efficacy: optimization of a series of 2-Aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)","volume":"54","author":"Cheng","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib38","unstructured":"The Compound 6-bromo-2-phenylquinoline-4-carboxylic Acid is Commercially Available from Merck, CAS Number: 33007-99-7."},{"key":"10.1016\/j.ejmech.2025.118144_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112759","article-title":"Synthesis of biphenyl oxazole derivatives via Suzuki coupling and biological evaluations as nucleotide pyrophosphatase\/phosphodiesterase-1 and -3 inhibitors","volume":"208","author":"Ahmad","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300165","article-title":"Synthesis of Thieno[3,2-d]pyrimidine derivatives through sequential SNAr and suzuki reactions as selective h-NTPDase inhibitors","volume":"18","author":"Zaman","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118144_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106196","article-title":"Identification of thienopyrimidine glycinates as selective inhibitors for h-NTPDases","volume":"129","author":"Begum","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118144_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142731","article-title":"Synthesis of 1,3,4-oxadiazole derivatives via transition metal catalyzed cross-coupling and their biological evaluation as selective inhibitors of Ecto-nucleoside triphosphate diphosphohydrolase (NTPDase)-2, -3 and -8 inhibitors","volume":"1344","author":"Ahmad","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118144_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118144_bib44","article-title":"Substrate specificity profiling of SARS-CoV-2 main protease enables design of activity-based probes for patient-sample imaging","author":"Rut","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ejmech.2025.118144_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2290910","article-title":"Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19","volume":"39","author":"Biernacki","year":"2024","journal-title":"J. Enzym. Inhib. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T22:45:39Z","timestamp":1772837139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":45,"alternative-id":["S0223523425009092"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118144","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigating SARS-CoV-2\u2013exacerbated neuroinflammation and Alzheimer's pathology: Synthesis of quinoline-based dual inhibitors targeting cysteine and aspartyl proteases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118144"}}